AbbVie Inc. (ABBV)

106.70
0.72 0.68
NYSE : Health Technology
Prev Close 105.98
Open 107.00
Day Low/High 106.20 / 107.25
52 Wk Low/High 64.80 / 125.86
Volume 1.22M
Avg Volume 6.97M
Exchange NYSE
Shares Outstanding 1.59B
Market Cap 165.32B
EPS 3.30
P/E Ratio 26.46
Div & Yield 3.84 (2.81%)

Latest News

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

KLA-Tencor, Microsoft and Intel all report earnings after the close Thursday.

AbbVie Submits Biologics License Application To U.S. FDA For Investigational Treatment Risankizumab For Moderate To Severe Plaque Psoriasis

- In clinical studies, more than half of patients receiving risankizumab achieved complete skin clearance (PASI 100) at one year (52 weeks) (1)

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

Mylan Spotlights Diversification at Investor Day

Mylan Spotlights Diversification at Investor Day

The drug company generates about 60% of revenue outside the U.S.

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.

AbbVie Announces Global Resolution Of HUMIRA® (adalimumab) Patent Disputes With Samsung Bioepis

AbbVie Announces Global Resolution Of HUMIRA® (adalimumab) Patent Disputes With Samsung Bioepis

- Agreements Provide Non-Exclusive License to Samsung Bioepis for HUMIRA-Related Intellectual Property in the U.S. Effective June 30, 2023, and in Other Markets on Different Dates

Amazon and Bank of America Are 2 of 16 Stocks Poised to Change Direction

Amazon and Bank of America Are 2 of 16 Stocks Poised to Change Direction

These names are displaying signs of either bullish or bearish reversal patterns over the past week.

Cannabis Investing: 2 of the Easiest Stocks to Buy to Play the Legal Weed Boom

Cannabis Investing: 2 of the Easiest Stocks to Buy to Play the Legal Weed Boom

The legal cannabis industry could be worth $24 billion by 2025. Are you willing to pass that up?

4 Strong Buy Biotech Stocks Poised to Explode

4 Strong Buy Biotech Stocks Poised to Explode

Here comes the growth. These four strong buy biotech stocks are potentially on the cusp of very big growth.

With Nothing to Buy, Everyone Sells: Cramer's 'Mad Money' Recap (Thur 3/22/18)

With Nothing to Buy, Everyone Sells: Cramer's 'Mad Money' Recap (Thur 3/22/18)

Jim Cramer calls it a tsunami of selling. Not one sector of the stock market got a break in Thursday's tariff-inspired decline.

AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu

AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu

Here's what you need to know now for Thursday, March 22.

Jim Cramer: When There's Nothing to Buy, People Sell

Jim Cramer: When There's Nothing to Buy, People Sell

No sector offered respite from Thursday's tariff-inspired selloff.

AbbVie's Cancer Drug Setback Provides Buying Opportunity

AbbVie's Cancer Drug Setback Provides Buying Opportunity

The biopharma company's shares took a dive on Thursday, March 22, after it said it will not seek accelerated approval for Rova-T in third-line relapsed/refractory small-cell lung cancer.

Jim Cramer: No Place to Go and Fewer Places to Hide

Jim Cramer: No Place to Go and Fewer Places to Hide

Just not a great day.

AbbVie And The International Myeloma Foundation Announce Partnership To Study The Role Of A Genetic Mutation In Outcomes Of Patients With Multiple Myeloma

AbbVie And The International Myeloma Foundation Announce Partnership To Study The Role Of A Genetic Mutation In Outcomes Of Patients With Multiple Myeloma

- Study is among the largest and most comprehensive in multiple myeloma (MM), and will assess outcomes from 1,500 patients with MM and the t(11;14) translocation at participating International Myeloma Foundation sites globally

AbbVie Announces Positive Topline Results From Second Phase 3 Study Evaluating Investigational Elagolix In Women With Uterine Fibroids

AbbVie Announces Positive Topline Results From Second Phase 3 Study Evaluating Investigational Elagolix In Women With Uterine Fibroids

- Second of two pivotal Phase 3 studies (ELARIS UF-II) met primary efficacy endpoint and all ranked secondary endpoints

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.

Julianne Hough Encourages Women To "Speak Up For Endo" During Endometriosis Awareness Month

Julianne Hough Encourages Women To "Speak Up For Endo" During Endometriosis Awareness Month

- Endometriosis affects an estimated one in 10 women of reproductive age, but diagnosis can take up to six to 10 years(1,2)

TheStreet Quant Rating: A- (Buy)